LENZ: Amendment: SEC Form SCHEDULE 13G/A filed by LENZ Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for LENZ
Across the 20 sessions after earlier LENZ headlines, the stock closed higher 8 times and lower 12 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LENZ | SPY |
|---|---|---|---|
| Aug 12, 2026 | LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | -3.3% | +0.3% |
| Aug 5, 2026 | LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 | +4.4% | -0.2% |
| Jul 6, 2026 | LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia | -4.9% | +0.9% |
| Jun 24, 2026 | LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand | -3.0% | -0.0% |
| Jun 8, 2026 | LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China | -4.1% | +0.2% |
| May 26, 2026 | LENZ Therapeutics to Participate in Upcoming Investor Conferences | +2.6% | +0.7% |
Quantisnow market dataNASDAQ
LENZ
LENZ Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for LENZ
Full LENZ profile on Quantisnow Follow LENZ and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time